Endocrine Abstracts vol 35

Endocrine
Abstracts
May 2014 Volume 35
ISSN 1479-6848 (online)
16th European Congress of
Endocrinology 2014
3 –7 May 2014, Wrocław, Poland
published by
bioscientifica
Online version available at
www.endocrine-abstracts.org
Volume 35
May 2014
Endocrine Abstracts
16th European Congress of
Endocrinology
3–7 May 2014, Wrocław, Poland
EDITORS
The abstracts were marked by the Abstract Marking Panel selected by the Programme Organising Committee
ECE 2014 Programme Organising Committee
Paolo Beck-Peccoz
Anna Spada
Chair
Chair
Members
Max Bielohuby
Justo Castan˜o
Niki Karavitaki
Marta Korbonits
Krzysztof Kula
Agnes Linlart
Sten Lund
Valeriya Lyssenko
Andrej Milewicz
Efisio Puxeddu
Hans Romjin
Allan Vaag
Peter Varnai
M Donath Switzerland
J Drouin Canada
L Duntas Greece
G Eisenhofer Germany
S Farooqi UK
M Felicia Italy
A Ferlin Italy
C Follin Sweden
J Frystyk Denmark
L Fugazzola Italy
C Gaston UK
A-P Gimenez-Roqueplo France
E Gregoraszczu Poland
S Hahner Germany
N Hamdy Netherlands
T Hansen Denmark
TK Hansen Denmark
B Hemmingsen
A Hoeflich Germany
L Hofbauer Germany
P-M Holterhus Germany
E S Husebye Norway
A Januszewic Poland
N Jessen Denmark
D Jezova
A Juul Denmark
G Kahaly Germany
F Karpe UK
M Keil
F Kelestimur Turkey
RD Kineman USA
P King UK
ST Knudsen Denmark
M Korbonits UK
K Kula Poland
J Lenders Netherlands
NR Leslie UK
A Luger Austria
RM Luque Spain
M Luster Germany
M Manelli Italy
C Mathieu Belgium
J Mittag Sweden
J Newell-Price UK
M Niedziela Poland
S Nielsen Denmark
E Nieschlag Germany
P Nilsson Sweden
S Pearce UK
S Petersenn Germany
JR Petrie UK
M Pfeifer Sweden
V Pirags Latvia
A Pizzocaro Italy
D Power Portugal
PL Poulsen Denmark
M Puig Spain
S Radian UK
M Robledo Spain
C Ronchi Italy
M Rossini Italy
D Salvatore Italy
L Sa¨vendahl Sweden
N Skakkebaek Denmark
J Smit Netherlands
R Sustarsic
N Taylor UK
J Toppari Finland
M Toth
Z Toth
M Tzanela Greece
AJ Van der Lely Netherlands
J van Eck Netherlands
V Volke Estonia
J L Wemeau France
I Wilkinson UK
Z Wu Germany
P Yeoh UK
J Young France
L Zabuilene
MC Zatelli Italy
C Zillikens Netherlands
Abstract Marking Panel
A Agha Ireland
M Albiero
M Alevizaki Greece
MS Andersen Denmark
F Antoni
A Beckers Belgium
I Bernabeu Spain
J Bertherat France
F Beuschlein Germany
M Bidlingmaier Germany
M Blomberg-Jensen
Netherlands
J Bollerslev Norway
C Bousquet France
T Brue France
C Buchanan UK
F Cardona
J Castano Spain
P Chanson France
M Charalambous UK
B Chini Italy
I Chiondini Italy
L Chiovato Italy
MS Cooper Australia
L Czupryniak Poland
C Daousi UK
MT Dattani UK
W De Herder Netherlands
16th European Congress of Endocrinology 2014, Wrocław, Poland
SPONSORS
The ESE would like to thank its Corporate Members and the ECE 2014 sponsors
ECE Corporate Members
Eli Lilly
Ipsen
Laboratoire HRA Pharma
Merck Serono
Novartis Pharmacueticals
Novo Nordisk
Pfizer
Sandoz International Gmbh
ViroPharma SPRL
Gold Sponsors
Ipsen
Novartis
Bronze Sponsors
Alexion
ESE Office
Euro House
22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK
ECE 2014 Secretariat
Bioscientifica Ltd
Euro House, 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK
Endocrine Abstracts (2014) Vol 35
Contact:
Tel:
Fax:
E-mail:
Web site:
Contact:
Tel:
Fax:
E-mail:
Website:
Andrea Davis
+44 (0)1454 642247
+44 (0)1454 642222
[email protected]
www.ese-hormones.org
Claire Arrigoni
+44 (0)1454 642240
+44 (0)1454 642222
[email protected]
http://www.bioscientifica.com
16th European Congress of Endocrinology 2014, Wrocław, Poland
CONTENTS
16th European Congress of Endocrinology 2014
PRIZE LECTURES AND BIOGRAPHICAL NOTES
The European Journal of Endocrinology Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . EJE1
The Geoffrey Harris Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GH1
PLENARY LECTURES
Genes, environment and endocrine disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Advances in molecular pathogenesis of thyroid cancer – therapeutic implications . . . . . . . . .
Good times, bad times: (patho)physiology of diurnal rhythms . . . . . . . . . . . . . . . . . . . .
Islet transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Simultaneous treatment of menopausal symptoms and prevention of breast cancer: Is it possible?
Hypothalamic inflammation - cause or consequence of obesity? . . . . . . . . . . . . . . . . . . .
Reproduction and energy metabolism, an ancestral balance to be preserved for women’s health .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
PL1
PL2
PL3
PL4
PL5
PL6
PL7
Endocrine changes and treatment needs in critically ill patients . . . . . . . . . . . . . . . . . . . .
Pituitary development – from basic research to clinical practice . . . . . . . . . . . . . . . . . . . .
News from thyroid hormones: central transport, energy control and oxidative stress . . . . . . . .
Endocrine Nurses Session 1: Craniopharyngioma . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Obesity Beyond BMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Focus on novel developments of PCOS - conclusions from the PCOS Task Force . . . . . . . . . . .
Nontumorous pituitary diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Membrane lipid composition and receptor function. Signalling and trafficking . . . . . . . . . . . .
EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target?
Difficulties in the treatment of Graves’ orbitopathy . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long term outcome of ‘cured’ pituitary patients . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gut microbiota in diabetes and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endocrine Nurse Session 3: Meet the Nurse Expert - Management of Endocrine Emergencies . . . .
Clinical outcome of medical intervention in Disorder of Sex Development (DSD) . . . . . . . . . . .
Thromboembolism and contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Metformin: old dog, new tricks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cushing’s syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endocrine disease during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Osteoporosis - An update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
New hormones and endocrine tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dilemmas in hormonal replacements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Novel therapies for thyroid cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Neuroendocrine tumours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nutrient regulation of metabolism and endocrine systems . . . . . . . . . . . . . . . . . . . . . . .
Gonadal hormones and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pitfalls in hormone measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Brown Adipose Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Molecular pathophysiology for clinicians: receptor-related disorders . . . . . . . . . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. S1.1– S1.3
. S2.1– S2.3
. S3.1– S3.3
. S4.1– S4.3
. S5.1– S5.3
. S6.1– S6.3
. S7.1– S7.3
. S8.1– S8.3
. S9.1– S9.3
S10.1– S10.3
S11.1– S11.3
S12.1– S12.3
S13.1– S13.3
S14.1– S14.3
S15.1– S15.3
S16.1– S16.3
S17.1– S17.3
S18.1– S18.3
S19.1– S19.3
S20.1– S20.3
S21.1– S21.3
S22.1– S22.3
S23.1– S23.3
S24.1– S24.3
S25.1– S25.3
S26.1– S26.3
S27.1– S27.3
S28.1– S28.3
SYMPOSIA
Endocrine Abstracts (2014) Vol 35
16th European Congress of Endocrinology 2014, Wrocław, Poland
MEET THE EXPERT SESSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MTE1 –MTE17
ORAL COMMUNICATIONS
Thyroid clinical . . . . . . . . .
Adrenal Clinical . . . . . . . . .
Neuroendocrinology & Signalling
Diabetes and Obesity 1 . . . . .
Adrenal & Thyroid . . . . . . . .
Bone, Calcium & Vitamin D . . .
IGF-1 and Thyroid Basic . . . .
Pituitary Clinical . . . . . . . . .
Reproduction . . . . . . . . . . .
Endocrine Tumours . . . . . . .
Diabetes and Obesity 2 . . . . .
Pituitary Basic . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. . OC1.1– OC1.5
. . OC2.1– OC2.5
. . OC3.1– OC3.5
. . OC4.1– OC4.5
. . OC5.1– OC5.5
. . OC6.1– OC6.5
. . OC7.1 OC7.5
. . OC8.1– OC8.5
. . OC9.1– OC9.5
OC10.1 – OC10.5
OC11.1 – OC11.5
OC12.1 – OC12.5
NURSE POSTERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N1–N8
POSTER PRESENTATIONS
Adrenal cortex . . . . . . . . . . . . . . . . . . . .
Adrenal Medulla . . . . . . . . . . . . . . . . . . .
Bone and Osteoporosis . . . . . . . . . . . . . . .
Calcium and Vitamin D metabolism . . . . . . . .
Cardiovascular Endocrinology & Lipid Metabolism
Clinical case reports – Pituitary / Adrenal . . . .
Clinical case reports – Thyroid / Others . . . . . .
Developmental Endocrinology . . . . . . . . . . .
Diabetes (epidemiology, pathophysiology) . . . . .
Diabetes complications . . . . . . . . . . . . . . .
Diabetes therapy . . . . . . . . . . . . . . . . . . .
Endocrine disruptors . . . . . . . . . . . . . . . . .
Endocrine tumours and neoplasia . . . . . . . . .
Female reproduction . . . . . . . . . . . . . . . . .
Growth hormone IGF axis – basic . . . . . . . . .
Male reproduction . . . . . . . . . . . . . . . . . .
Neuroendocrinology . . . . . . . . . . . . . . . . .
Nuclear receptors and signal transduction . . . . .
Obesity . . . . . . . . . . . . . . . . . . . . . . . .
Paediatric endocrinology . . . . . . . . . . . . . .
Pituitary – Basic (Generously supported by IPSEN) .
Pituitary – Clinical (Generously supported by IPSEN)
Steroid metabolism and action . . . . . . . . . . .
Thyroid (non-cancer) . . . . . . . . . . . . . . . .
Thyroid cancer . . . . . . . . . . . . . . . . . . . .
INDEX OF AUTHORS
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. .
. .
. .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. . . . P1– P56
. . . P57– P64
. . P65 – P100
. P101 – P168
. P169 – P209
. P210 – P260
. P261 – P332
. P333 – P339
. P340 – P402
. P403 – P461
. P462 – P501
. P502 – P513
. P514 – P613
. P614 – P667
. P668 – P683
. P684 – P708
. P709 – P735
. P736 – P739
. P740 – P792
. P793 – P825
. P826 – P836
. P837 – P945
. P946 – P957
. P958 –P1082
P1083 –P1152
16th European Congress of Endocrinology 2014, Wrocław, Poland
Poster Presentations
Endocrine Abstracts (2014) Vol 35
16th European Congress of Endocrinology 2014, Wrocław, Poland
P1053
Thyroid volume in adult b-thalassemic patients is smaller than in
controls
Anna Ansaloni1,2, Chiara Diazzi1,2, Daniele Santi1,2, Giulia Brigante1,2,
Francesca Ferrara3, Antonello Pietrangelo3 & Vincenzo Rochira1,2
1
Chair of Endocrinology and Metabolism, Department of Biomedical,
Metabolic and Neural Sciences, University of Modena and Reggio Emilia,
Modena, Italy; 2Division of Endocrinology Integrated, Department of
Medicine, Endocrinology and Metabolism, Geriatrics, Azienda USL of
Modena, NOCSAE of Baggiovara, Modena, Italy; 3Division of Internal
Medicine and Center for Hemochromatosis, ‘Mario Coppo’ Liver Research
Center, University Hospital of Modena, Modena, Italy.
Introduction
Thyroid function is commonly impaired in b-thalassemic patients with an
estimated prevalence of hypothyroidism of 9–11%. According to literature, iron
overload is the main cause of tissue damage involving both thyroid and pituitary
gland, thus leading to primary or secondary hypothyroidism respectively.
However, thyroid morphology has been rarely investigated in adults. The aim
of this study is to evaluate thyroid volume (TV) and thyroid morphology in
b-thalassemic adult patients compared to healthy controls.
Methods
We performed a cross-sectional, controlled study in 13 b-thalassemic adult
patients (six males and seven females) (36.36G4.26 years) and 120 healthy
volunteers (28 males and, 92 females) (38.1G4.9 years). All subjects underwent
thyroid ultrasonography performed by the same operator. TV was calculated as
the sum of the volume of the two lobes, each estimated by standardized formula:
length!width!depth!0.479. Ultrasound evaluation included the presence/
absence of hypoechogenicity and echotexture heterogeneity, and the presence/
absence of nodules.
Results
TV was significantly lower in b-thalassemic patients (5.41G1.33 ml) than in the
control group (8.45G2.81 ml) (P!0.001) independently from their thyroid
function (euthyroidism or hypothyroidism). The prevalence of diffuse echotexture
heterogeneity and hypoechogenicity of the thyroid was significantly higher in
thalassemic patients (92.3%) than in the control group (42.4%) (P!0.001).
Thyroid antibodies were negative in all thalassemic patients. Thyroid nodules
were found in four thalassemic patients (30.7%) and in 44 volunteers (36.7%)
(PZ0.674).
Discussion
In adult b-thalassemic patients TV was smaller than in healthy subjects even
when patients with a normal thyroid function were considered. Moreover
the prevalence of hypoechogenicity and echotexture heterogeneity, without a
confirmed diagnosis of autoimmune thyroiditis, was higher. These results suggest
a primary thyroid damage, characterized by thyroid hypoplasia and tissue
alterations probably caused by iron infiltrates. Furthermore, the risk of developing
thyroid nodules seems not to be increased in beta-thalassemic patients.
DOI: 10.1530/endoabs.35.P1053
P1054
Steroid treatment in patients with active moderate-to-severe Graves
orbitopathy
Theodora Tsirouki1, Zoi Giotaki3, Andreas Rizoulis2, Stelios Tigas3,
Ioannis Asproudis4, Agathocles Tsatsoulis3, Eftychia Kapsalaki5,
Evaggelia Tsironi1, Georgios N Koukoulis2 & Alexandra Bargiota2
1
Ophthalmology Clinic, University Hospital of Larisa, Larisa, Greece;
2
Endocrinology Clinic, University Hospital of Larisa, Larisa, Greece;
3
Endocrinology Clinic, University Hospital of Ioannina, Ioannina, Greece;
4
Ophthalmology Clinic, University Hospital of Ioannina, Ioannina, Greece;
5
Department of Diagnostic Radiology, University Hospital of Larisa, Larisa,
Greece.
Background
Although IV steroids are the treatment of choice for moderate-to-severe graves
orbitopathy (M-S GO), the most efficacious regimen is not yet defined. Cases not
responding or relapsing after steroid treatment (STx) are not uncommon and STx
can cause serious adverse events. The aim of the present study is to define the
steroid regimen which balances between efficacy and damage, using stir-sequence
orbital-MRI (SsMRIo) as an additional objective tool for the evaluation of activity
and severity of GO.
Endocrine Abstracts (2014) Vol 35
Methods
Forty-seven patients with M-S GO received a cumulative dose of 4.5 g of
methylprednisolone in 12 weekly doses. Two weeks post iv-STx, peros-STx
(prednisolone for 3 months) was administered to patients with clinical and MRI
findings of active disease. CAS and TES scores were measured at baseline, 6, 12
and 24 weeks and SsMRIo was performed at baseline and 12 weeks. Quality of
life was evaluated (GO-QoL questionnaire) at baseline, 12 and 24 weeks.
Results
Age was 58.46G13.37 (meanGS.D.), 70.2% were females and 37.8% current
smokers. Duration of ocular symptoms was 12.22G13.23 months. Owing
to adverse events 10.6%(5/47) discontinued iv-STx. Peros-STX following the
IV received 52.4% (22/42) based on the SsMRIo. At the end of the treatment
significantly better CAS (CAS at baseline: 6.06G1.17 and at 24 weeks:1.28G
1.55, P!0.001) and TES scores (TES at baseline:18.33G6.63 and at 24 weeks:
8.68G7.24, P!0.001) were observed. QoL significantly improved in all domains
(Social function at baseline: 3.77G2.79 and at 24 weeks: 7.45G2.98, PZ0.000,
dependency at baseline: 5.45G3.21, at 24 weeks: 9.05G2.19, PZ0.000).
Recurrence was comparable in the groups (2/22 and 2/20 patients after having and
not having received peros-STx).
Conclusions
Combination of iv-STX and peros-STx is an efficacious and safe regimen for the
treatment of GO. SsMRIo can improve the detection of those cases which remain
active and need further peros-STx after the iv-STX.
DOI: 10.1530/endoabs.35.P1054
P1055
The influence of radioiodine therapy in 1600 patients with subclinical
hyperthyroidism
Saeid Abdelrazek1, Piotr Szumowski1, Janusz Mysliewiec1,
Maria Kosciuszko2, Malgorzata Szelachowska2 & Maria Gorska2
1
Department of Nuclear Medicine, Medical University of Bialystok,
Bialystok, Poland; 2Department of Endocrinology Diabetolgy and Internal
Medicine, Medical University of Bialystok, Bialystok, Poland.
The aim of our study was to assess the influence of radioiodine (131I) therapy
on the achievement of euthyroidism, prevention of adverse effects on the
cardiovascular and prevent evolvement to overt hyperthyroidism.
Materials and methods
We treated 1600 patients refered to our department during the last 8 years, aged
23–77 years; 89% of them were females and 11% males; 520 patients with
multinodular goitre (MNG), and 1080 patients with autonomous nodule (ATN).
Some of the patients were treated with antithyroid drugs for 1–3 months before
131
I therapy (148 patients). Malignant changes were excluded in all nodules by
fine-needle aspiration biopsy. All the patients had serum TSH levels !0.1 mU/l
and effective T-half was more than 3 days at the time of treatment. The activity
dose was calculated by the use of Marinelli’s formula and ranged between 200
and 800 MBq. The absorbed dose (Gy) ranged between 180 and 300, and was
proportional to thyroid volume. Follow-up control was done every 6 weeks.
Results
Euthyroidism achieved in 99% of patient with ATN and 93% of MNG; 1% of
patients with ATN and 6% of patients with MNG develop hypothyroidism. One
percentage of patients with MNG were in subclinical hyperthyroidism and
received second dose of radioiodine therapy. In all of the patients, the symptoms
and signs of subclinical hyperthyroidism disappeared (palpitation, tachycardia,
atrial fibrillation, exercise tolerance improved, the blood pressure normalised and
the quality of life improved).
Conclusions
The achievement of euthyroidism and the remission of the symptoms and signs of
subclinical hyperthyroidism, were due to good diagnosis, well preparation of
the patients; accurate measurement of administered activity, effective half-life,
and well-organised follow-up. We recommend early treatment of subclinical
hyperthyroidism, and long period of follow-up to evaluate the long-term effect of
radioiodine therapy.
Subclinical hyperthyroidism, and long period of follow-up to evaluate the longterm effect of radioiodine therapy.
DOI: 10.1530/endoabs.35.P1055
16th European Congress of Endocrinology 2014, Wrocław, Poland
Author Index
Abaci, N P593
Abarikwu, S P708
Abbara, A OC3.1, OC9.4
& P617
Abbaszadegan, MR P108
Abdallah, NB P840
Abdelrazek, S P1041 &
P1055
Abdin, A P320 & P552
Abdollahi, M P405
Abdulla, H P848
Abeguile, G P148
Aberer, F P488
Aberle, J P581
Abeysinghe, P P786
Abi, A P472
Abouglila, K P846
Abrahamsson, N P770
Abraitiene, A P838
Abramavicius, S P369
Abreu, A P711
Abrosimov, AY P1108
Abs, R S21.3
Acar, B P343
Acar, FZ P1036 & P31
Acibucu, F P1120
Acikgoz, E P753
Ackermans, MT P946
Adamcova, M P22
Adamek, D P829
Adamidou, F P167
& P314
Adamska, A P134 & P663
Adamska, E OC4.1 & P776
Adas, G P14
Adas, M P14
Ademoglu, E P115
Adhiyaman, V P249
Adorini, L P696
Adukauskiene, D P931
Adversi, F P643
Ae Lee, K P1085
Aflorei, ED OC12.1
Afzal, N P1032
Agackiran, Y P136
Agapito, A P654 & P780
Agata, K P124
Agbaht, K P742
Aghaei, M P71
Aghajanova, Y P120 &
P477
Aghili, R P405
Agnieszka, C OC5.5
Aguiar, A P631
Aguilar-Diosdado, M
P206, P393, P395,
P398 & P496
Ahmed, A P1089
Ahmeti, I P248
Ahn, KJ P342 & P429
Aigelsreiter, A P192
Aimaretti, G P145
AiMin, X P771
Ajduk, M P785
Akc¸ay, G P66
Akbal, E P968
Akbay, E P270 & P271
Akcay, T P821
Akgul, OF P244, P245 &
P632
Akhtar, S P951
Akin, F OC9.5, P1027,
P263, P264 & P380
Akin, S P48 & P917
Akkurt, A P531
Akopyan, S P120
Akpinar, G P1010
Akpinar, S P275
Aksana, K P805
Aksoy, A P115
Aksyonova, E P778
Aktimur, R P126
Akturk, M P1030, P151,
P492 & P700
Akyildiz, M P171 & P172
Al-Dujaili, E P170
Al-Hayek, A P351
Al-Sabaan, F P351
Al-Saeed, A P351
Alacacioglu, A P332
Albarel, F P875
Alberiche, MdP P1073
Albersmeyer, M P868
Alborg, VC P909
Albrecht, E P739
Alebic, MS P686
Aled Rees, D OC5.2
Aleksandra, K OC5.5
Alesse, E P834 & P835
Alevizaki, M P1080 &
P1102
Alexander Iwen, K OC7.5
Alexandraki, K P537,
P598 & P608
Alexianu, M P815
Alexopoulou, O P860
Alfaro, JJ P467
Algu¨n, E P10
Alhumaidi, N P77
Ali Alhamza, AH P1
Ali Mansour, A P1
Ali, LA P542
Aliev, A P1050 & P584
Alikasifoglu, M P388
Alimova, N P358 & P417
Alkhalaf, F P77
Allelein, S P613
Allolio, B OC2.2, OC3.2,
OC5.3, P2, P533 &
P535
Almagro, RM P1002 &
P1003
Almanza, MR P909
Almeida, R P823, P926 &
P943
Almeida, T P654
Almomin, AMS P1
Alobedallah, A P351
Alonso, AA P575
Aloumanis, K P67 & P68
Alt-Tebacher, M P1042
Altas, A P1058
Altieri, B P535
Altinok, M P618
Altinova, A P446 & P492
Altinova, AE P1030 &
P151
Altun, B P968
Altunbas, HA P131, P74 &
P900
Altundal, N P894
Altunel, MS P432 & P433
Altunkaya, C P279 &
P285
Altunoren, O P238
Altuntas, Y P221 & P472
Alves, M P1009, P327,
P53, P546 & P547
Alves, MG P571
Alves, MR P702
Alves, R P461
Amani, MEA P984 & P985
Amar, L P49
Amaral, C P329, P457,
P764 & P769
Amaral, D P807
Amaral, FG P719
Amaro, T P1149
Ambroziak, U P338
Ammini, A P335
Ammini, AC P580 & P582
Amrani-Raissouni, T P106
Amselem, S P675
Amzar, D P543, P573 &
P893
Anaforog˘lu, P10, P23 &
P729
Anagnostis, P P167 &
P314
Anastasiu, D P65
Andersen, AS P337
Andersen, LLT P621
Andersen, M P618, P621
& P673
Andersen, MN OC1.2
Anderwald, C P129
Andrada, P P781
Andreas, B P714
Andreas, H P714
Andres, E P1042
Androulakis, I P641
Andrusiewicz, M P1119 &
P836
Andrysiak-Mamos, E
P100, P604 & P99
Andujar-Plata, P P731
Anelli, S P530
Angelini, F P937
Angelini, M S16.3
Angelopoulou, A P1102
Angelova, P P156
Anghel, GC P733
Anghel, R P734
Anheˆ, GF P719
Anil, C P403 & P468
Anna, S P180
Ansaloni, A P1053 &
P924
Ansari, NE P72
Antic, IB P299, P313,
P623, P624 & P625
Antic, S P828
Antiguedad, CG P445
Anton, M P814
Antonelou, M P920
Antosz, A P587
Antunes, A P823
Anwer, U P685 & P699
Aout, M P885 & P907
Apaydin, MA P863
Apollonatou, S P950
Apolloni, G P957
Apostolakis, M P1102
Arıkan, P958
Arau´jo-Vilar, D P811
Arabaci, E OC1.1
Aragu¨e´s, JM P350
Arakelyan, L P120
Aral, F P593
Aral, Y P385
16th European Congress of Endocrinology 2014, Wrocław, Poland
Regadera, J P738
Reghina, AD P431
Reimondo, G P8
Reincke, M MTE5, OC2.2,
OC5.4, P203, P37,
P564, P568 & P7
Reisch, N S14.1
Renata, C P1103
Rentziou, G P1102
Requena, JR P811
Requena, M P237 & P445
Rese´ndiz, KH P918
Resch, J OC7.5
Resmini, E OC12.5
Ress, C P861
Reyes-Garcı´a, R P91
Rezvani, R P773
Rheinheimer, J P365
Ribalta, MT P722
Ribeiro, C P1111
Riesco-Eizaguirre, G PL2
Ricciuti, A OC12.3
Richard, N P148
Richter-Unruh, A S14.1
Ricotti, R P145 & P27
Ridruejo, E P687
Ries, M P2
Rieske, P P97 & P98
Riester, A P37 & P568
Rigas, G P748
Rimpau, J P735
Rinaldi, E P47
Rinco´n-Ferna´ndez, D
P516
Rindi, G P549, P551 &
P578
Ripoll, RQ P909
Risbridger, G OC10.4
Ritvonen, E P881
Ritzel, K P7
Rivadeneira, L P237 &
P445
Rivera, NG P51 & P597
Rivera, R P741
Rivero-Corte´s, E OC12.2
Rivory, P P652
Rizoulis, A P1054
Rizvi, S P1031
Rizvi, SSR P1032, P685 &
P699
Roa, R P487
Roberts, J P914
Robledo, M P1095
Roca, M P500
Roca-Rodrı´guez, M P261
Roccio, M P27
Rochira, V P1053, P519,
P701, P924 & P955
Rodrı´guez Gutie´rrez, FJ
P1003
Rodrı´guez, C P1073
Rodrı´guez, E P1073
Rodrı´guez, JP P51 & P597
Rodrı´guez, R P322
Rodrı´guez-Medina, B
P695
Rodrı´guez-Molina, JM
P186
Rodrigues, D P1009,
P296, P325 & P327
Rodrigues, E P889
Rodrigues, P P17
Rodrigues, SC P719
Rodriguez, JP P498
Roemmler-Zehrer, J P735
Rogin´ska, D P54
Rogowicz-Frontczak, A
P378 & P420
Roine, R P881
Rojo-Martinez, G P789
Roma´n, MM P376
Romanelli, MMC P766
Romero, AO P743
Romero, MF P743
Romualdi, D P653
Ronchi, C OC2.3 & P533
Ronchi, CL OC2.2, OC5.3
& P535
Rosłonowska, E P557
Rosado, V P1095
Rosc, D P408
Rosca, R P204
Rosca, RI P529
Rosell, J P515
Rosenwald, A OC5.3
Roskosz, J OC1.5
& P1098
Roslon, M P1139
Ross, I P40
Ross, R P30 & P825
Ross, RJ OC5.2
Rossetti, P P1007
Rossetti, R P646
Rossi, M P692, P694 &
P704
Rossi, S P1126
Rostomyan, L P834
Roszak, M P1021
Rotermund, R P581
Rothenbuhler, A P140
Rotondi, S P834 & P835
Rousso, D P1047
Roux, A P652
Rozhinskaya, L P119, P24,
P730, P912, P919 &
P934
Rozhko, A P181
Rozkowszka, K P557
Ruas, L P1008, P1009,
P1111 & P296
Rubin, B P12 & P536
Rubino, M P128
Ruby, LCH P771
Ruchała, M P1035,
P1044, P1119, P202,
P338, P36, P836,
P982 & P983
Ruchala, M P326, P563,
P996 & S10.2
Rudnicka, M P99
Rudnik, A P832
Rudzinska, M P1131 &
P1135
Rudzki, G P254, P258 &
P556
Ruiz-Riquelme, A P811
Rupa, R P849
Ruprecht, Z P408
Rusak, M P776 & P818
Rusakov, V P266, P267
& P268
Rusalenko, M P181
Rusinek, D OC3.5 & P1152
Rusu, C P795, P814
& P819
Ruszkowska-Ciastek, B
P408
Ruszniewski, P P577
& P578
Rutishauser, J OC3.2
& P18
Rutkowska, A P511
Rutkowska, B P952
Rutter, M OC11.2
Ruvo, MD P831
Rybalchenko, V P422
Rybka, J P372
Rybka, W P372
Rydzanicz, M P338
Rymaszewska, J P127
& P930
Rys, A P157, P309 &
P777
Ryu, OH P384
Ryzhenkova, MI P1108
Sa´, J P389 & P390
Sa´daba, MC P669
Sa´nchez, A P1073
Sa´nchez, F P205
Sa´nchez, JRC P575
Sa´nchez, R P1073
Sa´nchez-Garcı´a, F P515
Sa´nchez-Iglesias, S P811
Sa´nchez-Zambrano, M
P205
Sa´sikova´, M P884
Se˛siadek, M P890
Słapa, R P557
Słoka, N P127
Słowin´ska-Srzednicka, J
P557
Sørensen, H P673
Sørensen, JA P621
Saad, F P478, P696, P754
& P755
Saaid, N P107
Saavedra, A P936
Sabino, T P654 & P780
Sabir, I P335
Sabt, A P77
Sacchi, S P639
Sacikara, M P136, P305,
P635, P980 & P987
Sadikova, E P142 & P375
Sadowski, T P160
Sadurska, E P1004
Sadykova, A P417 & P418
Saeger, W P901
Safari, R P71
Sag, S P753
Sagala, M P806
Saglam, F P1065, P305,
P421, P78 & P981
Sagliker, HS P231 & P301
Sahin, D P442
Sahin, F P69
Sahin, H P244 & P295
Sahin, I P1048 & P490
Sahin, M OC8.3, P139,
P146, P183, P228,
P230, P231, P238,
P244, P245, P295,
P301, P437, P5, P632,
P638 & P994
Saini, S P746
Saito, H P76
Sajardo, RB P575
Sajevets, T P277
Sajid, W P337
Sak, SD P61
Sakamoto, M P232 &
P897
Sakamoto, N P232
Saklamaz, A P171 & P172
Sala, E P845 & P898
Sala, GBL P643
Salam, R P107 & P959
Salas, MS P237 & P445
Salas-Salvado´, J S29.1
Salcuni, AS P81
Salgado, C P1149

Download Report